JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 80 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.45 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $2,000 | 0.0% | 380 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | -33.3% | 380 | -54.8% | 0.00% | – |
| Q1 2019 | $3,000 | 0.0% | 841 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -40.0% | 841 | +6.7% | 0.00% | – |
| Q3 2018 | $5,000 | -16.7% | 788 | -2.1% | 0.00% | -100.0% |
| Q2 2018 | $6,000 | -66.7% | 805 | -0.1% | 0.00% | – |
| Q1 2018 | $18,000 | +500.0% | 806 | +231.7% | 0.00% | – |
| Q4 2017 | $3,000 | – | 243 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |